Paper No. \_\_\_\_ Filed: January 2, 2019

## UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA, INC. and AKORN INC.,<sup>1</sup>
Petitioners,

v.

ALLERGAN, INC., Patent Owner.

Case IPR2016-01127 (US 8,685,930 B2)

Case IPR2016-01128 (US 8,629,111 B2)

Case IPR2016-01129 (US 8,642,556 B2)

Case IPR2016-01130 (US 8,633,162 B2)

Case IPR2016-01131 (US 8,648,048 B2)

Case IPR2016-01132 (US 9,248,191 B2)


#### PETITIONERS' UPDATED EXHIBIT LIST

<sup>1</sup> Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).



## LIST OF EXHIBITS

Exhibit No.	Description
1001	The Patent (U.S. Patent No. 8,685,930; 8,629,111; 8,642,556; 8,633,162; 8,648,048; or 9,248,191 to Acheampong <i>et al.</i> , in IPR2016-01127 – IPR2016-01132, respectively)
1002	Declaration of Dr. Mansoor Amiji
1003	Curriculum Vitae of Dr. Mansoor Amiji
1004	File History (U.S. Patent No. 8,685,930; 8,629,111; 8,642,556; 8,633,162; 8,648,048; or 9,248,191 to Acheampong <i>et al.</i> , in IPR2016-01127 –01132, respectively)
1005	File history of U.S. Patent Application No. 10/927,857, filed on August 27, 2010 to Acheampong <i>et al</i> .
1006	U.S. Patent No. 5,474,979 to Ding et al., filed May 17, 1994
1007	Sall, K., et al., Two Multicenter, Randomized Studies of the Efficacy and Safety of Cyclosporine Ophthalmic Emulsion in Moderate to Severe Dry Eye Disease, 107 Ophthalmol. 631 (2000)
1008	Acheampong, A., et al., Cyclosporine distribution into the conjunctiva, cornea, lacrimal gland, and systemic blood following topical dosing of cyclosporine to rabbit, dog, and human eyes, 2 Lacrimal Gland, Tear Film, and Dry Eye Syndromes 1001 (1998)
1009	U.S. Patent No. 5,578,586 to Glonek et al., filed February 4, 1994
1010	U.S. Patent No. 5,981,607 to Ding et al., filed January 20, 1998
1011	Kaswan, R., Intraocular Penetration of Topically Applied Cyclosporine 20 Transpl. Proc. 650 (1988)



Kunert, K., et al., Analysis of Topical Cyclosporine Treatment of Patients with Dry Eye Syndrome 118 ARCH OPHTHALMOL 1489 (2000)
Physicians' Desk Reference for Ophthalmic Medicines (1999)
Turner, K., et al., Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion 19 CORNEA 492 (2000)
Stevenson, D., et al. Efficacy and Safety of Cyclosporin A Ophthalmic Emulsion in the Treatment of Moderate-to-Severe Dry Eye Disease 107 Ophthalmol. 967 (2000)
Remington's 20 <sup>th</sup> Edition: The Science and Practice of Pharmacy (A. Gennaro ed. 2003)
Goto, E., et al. Low-Concentration Homogenized Castor Oil Eye Drops for Noninflamed Obstructive Meibomian Gland Dysfunction 109 Ophthalmol. 2030 (2002)
Kanpolat, A., et al., Penetration of Cyclosporin A into the Rabbit Cornea and Aqueous Humor after Topical Drop and Collagen Shield Administration 20 CLAO J. 119 (1994)
Vieira, A., et al., Effect of ricinoleic acid in acute and subchronic experimental models of inflammation, 9 MED. INFLAMM. 223 (2000)
Murphy, R., The Once and Future Treatment of Dry Eye, REVIEW OF OPTOMETRY 1 (2000)
Small, D., et al., Blood concentrations of Cyclosporin A During Long-Term Treatment with Cyclosporin A Ophthalmic Emulsions in Patients with Moderate to Severe Dry Eye Disease 18 J. Oc. Pharm. Therap. 411 (2002)
Stedman's Medical Dictionary 27 <sup>th</sup> Edition (M.B. Pugh ed. 2000)



1023	Complaint; Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Apotex, Inc., Apotex Corp., Akorn, Inc., Mylan Pharmaceuticals Inc., and Mylan Inc., No. 2:15-cv-01455
1024	Approved Drug Products with Therapeutic Equivalence Evaluations (34th Ed.) (2014) (Excerpts)
1025 (IPR2016- 01127)	File history of U.S. Patent No. 8,629,111 to Acheampong <i>et al</i> . (Exhibit Number Reserved in IPR2016-01128, -01129, -01130, & -01131)
1025 (IPR2016- 01132)	Complaint; Allergan, Inc. v. Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd., Apotex, Inc., Apotex Corp., Akorn, Inc., Mylan Pharmaceuticals Inc., No. 2:15-cv-01455 (Exhibit Number Reserved in IPR2016-01128, -01129, -01130, & -01131)
1026	Reserved
1027	Allergan Department of Pharmacokinetics and Drug Metabolism Departmental Research Report, Report No: PK-00-163, Concentrations of Cyclosporin A in Cornea and Conjunctiva After a Single Ophthalmic Dose to New Zealand White Rabbits: Evaluation of 7 Ophthalmic Emulsion Formulations
1028	PROTECTIVE ORDER MATERIAL - Allergan R&D Records Management, Notebook Number L-2000-7626
1029	PROTECTIVE ORDER MATERIAL - Allergan R&D Records Management, Notebook Number L-1998-5709
1030	PROTECTIVE ORDER MATERIAL - Allergan R&D Records Management, Notebook Number L-1998-5707
1031	PROTECTIVE ORDER MATERIAL - Allergan R&D Records Management, Notebook Number L-2000-7726
1032	Orange Book 29 <sup>th</sup> Edition (2009) (excerpts)
1033	Mayssa Attar Professional Linkedin Profile



1034	PROTECTIVE ORDER MATERIAL - Transcript of May 31, 2017 Deposition of Robert S. Maness, Ph.D.
1035	PROTECTIVE ORDER MATERIAL - Transcript of June 1, 2017 Deposition of Rhett Schiffman, M.D., M.S.Sc.
1036	PROTECTIVE ORDER MATERIAL - Transcript of June 7, 2017 Deposition of Thorsteinn Loftsson, Ph.D.
1037	Transcript of June 20, 2017 Deposition of John D. Sheppard, M.D., M.S.Sc.
1038	PROTECTIVE ORDER MATERIAL - Transcript of June 22, 2017 Deposition of Mayssa Attar, Ph.D.
1038	REDACTED - Transcript of June 22, 2017 Deposition of Mayssa Attar, Ph.D.
1039	PROTECTIVE ORDER MATERIAL - Declaration of Andrew F. Calman, M.D.
1040	PROTECTIVE ORDER MATERIAL - Declaration of Daniel A. Bloch, Ph.D.
1041	PROTECTIVE ORDER MATERIAL - Declaration of Ivan T. Hofmann
1042	Curriculum Vitae of Andrew F. Calman, M.D.
1043	Curriculum Vitae of Daniel A. Bloch, Ph.D.
1044	Curriculum Vitae of Ivan T. Hofmann
1045	Facts About Dry Eye, NATIONAL EYE INSTITUTE OFFICE OF SCIENCE COMMUNICATIONS, PUBLIC LIAISON, AND EDUCATION, 2013, https://nei.nih.gov/health/dryeye/dryeye (accessed June 26, 2017)
1046	Niederkorn, et al., Desiccating Stress Induces T Cell-Mediated Sjögren's Syndrome-Like Lacrimal Keratoconjunctivitis, 176 J. IMMUNOL. 3950 (2006)



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

#### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

